Roth Capital analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals (SYRS) yesterday and set a price target of $14. The company’s shares closed on Friday at $6.81, close to its 52-week low of $6.25.
Marango noted:
“We believe that today’s unexpectedly positive preliminary data from SY-1425 + HMAs in AML deserves an incremental premium, especially when considering the Street’s generally low expectations going into ASH.”
According to TipRanks.com, Marango is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.4% and a 23.1% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syros Pharmaceuticals with a $20.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.60 and a one-year low of $6.25. Currently, Syros Pharmaceuticals has an average volume of 119.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
